Table 5 Comparison of probabilistic and deterministic outcomes over a 5-year horizon
Mean outcome | Probabilistic [95% CrI] | Deterministic |
|---|---|---|
Total discounted cost, eptinezumab | £41,270 [£26,272: £57,560] | £41,804 |
Total discounted cost, BSC | £46,620 [£26,087: £68,770] | £46,698 |
Discounted QALYs, eptinezumab | 2.70 [2.43: 2.98] | 2.72 |
Discounted QALYs, BSC | 2.46 [2.07: 2.84] | 2.49 |
Incremental costs | –£5,350 [–£11,647: £503] | –£4,894 |
Incremental QALYs | 0.237 [0.071: 0.436] | 0.231 |
ICER | Dominant in the SE quadrant | Dominant in the SE quadrant |
Net monetary benefit @ £20,000 | £10,085 | £9,515 |